CYBB Rabbit Polyclonal Antibody

CAT#: TA327116

Rabbit anti-CYBB Polyclonal Antibody

Size: 20 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

热销推荐

CNY 1999.00

CNY 2700.00


货期*
2周

规格
    • 100 ul

Product images

推荐一起购买 (1)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1430.00

Specifications

Product Data
Applications ELISA, ICC/IF, IHC, WB
Recommend Dilution WB,1:500 - 1:1000
IHC-P,1:50 - 1:200
IF/ICC,1:50 - 1:200
ELISA,Recommended starting concentration is 1 μg/mL. Please optimize the concentration based on your specific assay requirements.
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Isotype IgG
Formulation Buffer: PBS with 0.09% Sodium azide,50% glycerol,pH7.3.
Concentration lot specific
Purification Affinity purification
Conjugation Unconjugated
Storage Condition Store at -20℃. Avoid freeze / thaw cycles.
Predicted Protein Size 65kDa
Gene Name cytochrome b-245 beta chain
Background Cytochrome b (-245) is composed of cytochrome b alpha (CYBA) and beta (CYBB) chain. It has been proposed as a primary component of the microbicidal oxidase system of phagocytes. CYBB deficiency is one of five described biochemical defects associated with chronic granulomatous disease (CGD). In this disorder, there is decreased activity of phagocyte NADPH oxidase; neutrophils are able to phagocytize bacteria but cannot kill them in the phagocytic vacuoles. The cause of the killing defect is an inability to increase the cell's respiration and consequent failure to deliver activated oxygen into the phagocytic vacuole.
Synonyms AMCBX2; CGD; GP91-1; GP91-PHOX; GP91PHOX; IMD34; NOX2; p91-PHOX
Reference Data
Protein Families Druggable Genome, Ion Channels: Other, Transmembrane
Protein Pathways Leukocyte transendothelial migration
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...